The FDA cleared Optune Pax on February 12, the first device ever approved to treat locally advanced pancreatic cancer. Novocure’s wearable delivers alternating electrical fields to the abdomen, physically disrupting cancer cell division without surgery or radiation.
The approval came through the PMA pathway, the FDA’s most rigorous device review process. The pivotal trial showed that adding TTFields to standard chemotherapy extended overall survival by about two months compared to chemo alone — modest, but in pancreatic cancer (51,980 expected deaths in 2025), two months is what the field calls a win.
Novocure has been trying to prove the approach works in other solid tumors for years. A second PMA across a completely different cancer type validates the mechanism, not just the device, and signals that regulators are willing to keep rewarding the science.
The device is wearable and portable, designed for home use, fitting neatly into FDA’s own “Home as a Health Care Hub” initiative — which could smooth review timelines for similar portable oncology devices down the line.
Novocure got Breakthrough Device designation in December 2024. Approved fourteen months later.